Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
Standard
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). / Laarhoven, van; Fiedler, Walter; Fiedler, Walter; Desar, Ingrid M E; Asten, van; Jack, J A; Marréaud, Sandrine; Lacombe, Denis; Govaerts, Anne-Sophie; Bogaerts, Jan; Lasch, Peter; Timmer-Bonte, Johanna N H; Lambiase, Antonio; Bordignon, Claudio; Punt, Cornelis J A; Heerschap, Arend; Herpen, van; Carla, M L.
in: CLIN CANCER RES, Jahrgang 16, Nr. 4, 4, 2010, S. 1315-1323.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
AU - Laarhoven, van
AU - Fiedler, Walter
AU - Fiedler, Walter
AU - Desar, Ingrid M E
AU - Asten, van
AU - Jack, J A
AU - Marréaud, Sandrine
AU - Lacombe, Denis
AU - Govaerts, Anne-Sophie
AU - Bogaerts, Jan
AU - Lasch, Peter
AU - Timmer-Bonte, Johanna N H
AU - Lambiase, Antonio
AU - Bordignon, Claudio
AU - Punt, Cornelis J A
AU - Heerschap, Arend
AU - Herpen, van
AU - Carla, M L
PY - 2010
Y1 - 2010
N2 - This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.
AB - This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.
M3 - SCORING: Zeitschriftenaufsatz
VL - 16
SP - 1315
EP - 1323
JO - CLIN CANCER RES
JF - CLIN CANCER RES
SN - 1078-0432
IS - 4
M1 - 4
ER -